科研成果
  成果统计  
  获奖
  论文
  专著
  专利
  新品种
  软件著作权
  成果转化  
  成果
  案例
  动态
  · 最新动态
  · 人才招聘
  · 专题
  ·
  · 学会学报
  · 信息服务
  您现在的位置:首页 > 科研成果 > 论文
 
论文编号:
作者:
作者: Zhang, Yongli; Chen, Guilin; Ma, Hong; Guo, Mingquan*
作者所在部门:
作者所在部门:
通讯作者:
通讯作者: Guo, Mingquan
刊物名称:
刊物名称: MOLECULES
论文题目:
论文题目: Antiproliferative and Enzyme Docking Analysis of Engleromycin from Engleromyces goetzei
摘要:
摘要:

Engleromyces goetzei P. Henn. (E. goetzei) has been widely used as a traditional herb for many years in Kenya due to its diverse biological effects. Although engleromycin was first isolated from E. goetzei in 1980, its pharmacological activity is still unknown. In this study, engleromycin from E. goetzei was identified by spectroscopic analyses, and subsequently examined for its antiproliferative activity using human cancer cell lines of SGC-7901, HT-29, HeLa and A549. As a result, it was revealed that engleromycin strongly inhibited the growth of SGC-7901, HT-29, HeLa and A549 cells with IC50 values at 26.77 ± 1.69 μM, 7.73 ±0.18 μM, 7.00 ± 0.12 μM and 3.14 ± 0.03 μM, respectively. The results of topoisomerase II (Top II) inhibition assay in vitro implied that engleromycin might be a Top II inhibitor. Further insights into the potential mechanism of antiproliferative activity displayed that engleromycin could dock into the binding pockets of Top II, like the clinical inhibitor doxorubicin, and then inhibit the biological activity of Top II. Taken together, our findings suggest that engleromycin has an anticancer potential, and may serve as a leading compound for the development of antitumor agents. 

年: 2019
卷: 24
期: 1
页:
收录类别:
影响因子:
论文出处:
论文出处:
外单位作者单位:
外单位作者单位:
备注:

关闭窗口